Biopharmaceutical company Gilead Sciences is expanding the availability of its COVID-19 treatment Remdesivir in India amid the country’s spike in cases. Gilead (GILD) …
Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in the treatment …
Gilead and Novo Nordisk are expanding their clinical collaboration for non-alcoholic steatohepatitis (NASH). Shares of Gilead, a biopharmaceutical company, are down about 1.
Kite, a unit of Gilead Sciences, announced that the US Food and Drug Administration (FDA) has approved its Yescarta T cell immunotherapy. The …
Gilead Sciences posted fourth quarter and full year results yesterday that surpassed analysts’ expectations, largely driven by sales of its COVID-19 treatment, Remdesivir, …
Gilead Sciences raised its full-year 2020 profit forecast on Monday fueled by demand for its remdesivir treatment during the COVID-19 pandemic. Shares rose …
Gilead Sciences lowered its 2020 guidance due to the global progression of the COVID-19 pandemic and uncertainty in forecasting sales of remdesivir, its …
Gilead Sciences (GILD) has announced that the U.S.
Gilead Sciences has inked a joint procurement agreement (JPA) with the European Commission (EC) for the supply of up to 500,000 treatment courses …
The focus and resources of several biotech and pharma companies have shifted toward developing a vaccine or treatment for COVID-19. However, there are …
